[Importance of recombinant proteins in the adjuvant treatment of cancer].
The clinical application of hematopoietic growth factors, which decrease the duration (and severity) of chemotherapy-induced myelosuppression, was made possible by using genetically-modified micro-organisms to produce them (e.g. epoietin). The interest of these products is double: in attenuating the myelosuppression, they decrease the risk of severe infectious complications; the better hematologic tolerance allows to deliver chemotherapy in higher doses that maximize tumoricidal activity.